Enfusion, Inc. (NYSE:ENFN) COO Neal Pawar Sells 2,769 Shares

Enfusion, Inc. (NYSE:ENFN) COO Neal Pawar sold 2,769 shares of Enfusion stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $11.48, for a total value of $31,788.12. Following the completion of the transaction, the chief operating officer now owns 1,231,627 shares in the company, valued at $14,139,077.96. The trade was a 0.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Neal Pawar also recently made the following trade(s):

• On Wednesday, March 5th, Neal Pawar sold 14,560 shares of Enfusion stock. The stock was sold at an average price of $11.38, for a total value of $165,692.80.
• On Wednesday, March 5th, Neal Pawar sold 14,560 shares of Enfusion stock. The stock was sold at an average price of $11.38, for a total value of $165,692.80.

Enfusion Trading Down 0.5 %

NYSE ENFN opened at $11.24 on Friday. The stock’s 50 day moving average is $10.98 and its two-hundred day moving average is $9.88. The company has a market capitalization of $1.44 billion, a price-to-earnings ratio of 280.95, a PEG ratio of 1.85 and a beta of 0.95. Enfusion, Inc. has a 1-year low of $7.83 and a 1-year high of $11.80.

Enfusion (NYSE:ENFN) last released its quarterly earnings data on Monday, March 3rd. The company reported $0.01 earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). The company had revenue of $52.94 million for the quarter, compared to analyst estimates of $53.98 million. Enfusion had a net margin of 1.70% and a return on equity of 6.67%. On average, analysts predict that Enfusion, Inc. will post 0.06 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on ENFN shares. William Blair restated a “market perform” rating on shares of Enfusion in a research note on Monday, January 13th. Piper Sandler boosted their price target on Enfusion from $10.00 to $11.50 and gave the company a “neutral” rating in a research note on Monday, December 23rd. Finally, Stifel Nicolaus boosted their price target on Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, December 18th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, Enfusion has a consensus rating of “Hold” and a consensus price target of $11.13.

Institutional Investors Weigh In On Enfusion

A number of institutional investors have recently added to or reduced their stakes in ENFN. Geode Capital Management LLC boosted its holdings in shares of Enfusion by 7.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,029,366 shares of the company’s stock worth $9,770,000 after acquiring an additional 70,367 shares in the last quarter. Wellington Management Group LLP boosted its holdings in shares of Enfusion by 6.7% in the 3rd quarter. Wellington Management Group LLP now owns 976,296 shares of the company’s stock worth $9,265,000 after acquiring an additional 61,032 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Enfusion by 612.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 208,022 shares of the company’s stock worth $1,974,000 after acquiring an additional 178,821 shares in the last quarter. Barclays PLC boosted its holdings in shares of Enfusion by 251.4% in the 3rd quarter. Barclays PLC now owns 86,039 shares of the company’s stock worth $817,000 after acquiring an additional 61,554 shares in the last quarter. Finally, PDT Partners LLC acquired a new position in shares of Enfusion in the 3rd quarter worth approximately $867,000. 81.05% of the stock is owned by institutional investors and hedge funds.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.